Caner Acar

18PUBLICATIONS
117CO-AUTHORS
Solid tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Apr 20, 2026
Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours.

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

|Jan 08, 2026
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events.

Caner Acar, Gökhan Şahin, Haydar Çağatay Yüksel

|Dec 12, 2025
Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment.

Caner Acar, Fatma Pinar Açar, Gökhan Şahin

|Dec 10, 2025
Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors.

Fatma Pinar Açar, Caner Acar, Haydar Çağatay Yüksel

|Nov 17, 2025
Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel

Pageof 3

Frequent Collaborators

15 joint publications

Haydar Çağatay Yüksel

15 joint publications

Gökhan Şahin

8 joint publications

Burçak Karaca

7 joint publications

Pınar Açar